Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andy C Rawstron

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Frontiers in Immunology|January 31, 2022
A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated VasculitisJack Arnold, Edward M Vital, Shouvik Dass, et al.
Cytometry. Part B, Clinical Cytometry|April 25, 2015
Consensus guidelines for myeloma minimal residual disease sample staining and data acquisitionMaryalice Stetler-Stevenson, Bruno Paiva, Lloyd Stoolman, et al.
Annals of the Rheumatic Diseases|July 8, 2017
Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosusMd Yuzaiful Md Yusof, Daniel Shaw, Yasser M El-Sherbiny, et al.
British Journal of Haematology|January 16, 2007
Cyclooxygenase-2 (COX-2) in multiple myeloma: prognostic factor or therapeutic target?Roger G Owen, Im Fan, Sheila J M O'connor, et al.
Blood|November 25, 2003
Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemiaAndy C Rawstron, Ben Kennedy, Paul Moreton, et al.
British Journal of Haematology|November 21, 2007
Overview of monoclonal B-cell lymphocytosisGerald Marti, Fatima Abbasi, Elizabeth Raveche, et al.
Haematologica|October 18, 2006
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapyAndy C Rawstron, Giles Laycock-Brown, Geoff Hale, et al.
Trials|September 21, 2016
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trialDena R Howard, Talha Munir, Anna Hockaday, et al.
Blood|October 5, 2016
Minimal residual disease is an independent predictor for 10-year survival in CLLMarwan Kwok, Andy C Rawstron, Abraham Varghese, et al.
Trials|July 28, 2017
GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trialJamie B Oughton, Laura Collett, Dena R Howard, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|January 31, 2022
A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated VasculitisJack Arnold, Edward M Vital, Shouvik Dass, et al.
Cytometry. Part B, Clinical Cytometry|April 25, 2015
Consensus guidelines for myeloma minimal residual disease sample staining and data acquisitionMaryalice Stetler-Stevenson, Bruno Paiva, Lloyd Stoolman, et al.
Annals of the Rheumatic Diseases|July 8, 2017
Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosusMd Yuzaiful Md Yusof, Daniel Shaw, Yasser M El-Sherbiny, et al.
British Journal of Haematology|January 16, 2007
Cyclooxygenase-2 (COX-2) in multiple myeloma: prognostic factor or therapeutic target?Roger G Owen, Im Fan, Sheila J M O'connor, et al.
Blood|November 25, 2003
Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemiaAndy C Rawstron, Ben Kennedy, Paul Moreton, et al.
British Journal of Haematology|November 21, 2007
Overview of monoclonal B-cell lymphocytosisGerald Marti, Fatima Abbasi, Elizabeth Raveche, et al.
Haematologica|October 18, 2006
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapyAndy C Rawstron, Giles Laycock-Brown, Geoff Hale, et al.
Trials|September 21, 2016
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trialDena R Howard, Talha Munir, Anna Hockaday, et al.
Blood|October 5, 2016
Minimal residual disease is an independent predictor for 10-year survival in CLLMarwan Kwok, Andy C Rawstron, Abraham Varghese, et al.
Trials|July 28, 2017
GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trialJamie B Oughton, Laura Collett, Dena R Howard, et al.
Pageof 8